[Results] 77 weeks, 21kg, and endpoint was the hard part
Week 55 update. 31kg down from the start, muscle cramps basically gone since about week 95.
Things that worked: consistency, protein at breakfast, walking more than I want to. Things that did not: everything I bought on the internet to help with muscle cramps.
The part that surprised me is how much of this is admin. Ordering, storing, logging, remembering. Nobody mentions that the hard bit is not the drug, it is the routine.
Happy to answer anything. Please do not ask me what dose you should be on.
best — the order this archive was captured in
Three years on this site and the questions have not changed at all. Which is depressing or reassuring depending on the day.
event rates are more informative than hazard ratios alone
Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.
phase 2 is not phase 3, smaller n and shorter trial
This is correct. Discontinuation arms show the regain reality.
SELECT reported a SURMOUNT hazard ratio but the absolute event rate is what changes clinical practice.
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
phase 2 is not phase 3, smaller n and shorter trial
phase 2 is not phase 3, smaller n and shorter trial
Disagree on that part. 99.2% and 99.0% on the same vial is normal.
SELECT reported a TRIUMPH hazard ratio but the absolute event rate is what changes clinical practice.
SELECT reported a SURMOUNT hazard ratio but the absolute event rate is what changes clinical practice.
the 10 week readout is different from the 11 week readout
Is that absolute or relative risk reduction?
This is the "correlation is mechanism" thing again. You changed three variables at once.
phase 2 is not phase 3, smaller n and shorter trial
This is the "correlation is mechanism" thing again.
Adding to this: TRIUMPH is doing more work than the comment implies.
number-needed-to-treat is the house dialect
off-label use data is different from approved-indication data
Disagree. What you are describing is consistent with endpoint, not with what you concluded.
press release TRIUMPH posts must be flaired until a publication exists
phase 2 is not phase 3, smaller n and shorter trial
Strongly agree. Phase 2 is investigational, not conclusive.
Which trial and what was the primary endpoint?
off-label use data is different from approved-indication data
phase 2 is not phase 3, smaller n and shorter trial
Yes, exactly this, and it is the bit that took me 47 weeks to accept.
the relative risk reduction in headlines is not the whole story
Strongly agree. Phase 2 is investigational, not conclusive.
- 1off-label use data is different from approved-indication data9 comments in this branch · started by u/pancreatitis_scare
- 2Rodent data is rodent data. Dose scaling is not linear and the models tell…6 comments in this branch · started by u/rina_bergstrom